
    
      This protocol is replacing NCT00582504.

      The study population will consist of USAMRIID and qualified extramural participants who are
      at risk of exposure to VEE virus. This study will be performed at the USAMRIID SIP Clinic.
      This open-label study represents a continuation of previous research conducted at USAMRIID.
      Subjects will be vaccinated with 0.5 mL of VEE vaccine, Live, Attenuated TC-83, NDBR 102, Lot
      4, Run 3 subcutaneously in the upper outer aspect of the triceps region. Subjects will
      contacted the following day and weekly for 4 weeks to assess for adverse events.
    
  